SteadyMed Ltd. is a specialty pharmaceutical company. It focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs.

History

SteadyMed Ltd. was incorporated in 2006 and is headquartered in San Ramon, California, USA. It is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs.

Mission

Our mission is to develop and commercialize life-enhancing pharmaceutical products to improve the lives of patients suffering from orphan and high-value diseases.

Vision

Our vision is to become a leader in the advancement of patient-centric and value-creating pharmaceutical solutions for unmet medical needs around the world.

Key Team

Ian Solomon (Founder)

Yossi Aldar (Founder)

Recognition and Awards

In 2017, SteadyMed was recognized as the winner of the SCRIP Award for Most Innovative Biotech Company for its Trevyent pressure-based, impervious drug delivery platform. In 2018, SteadyMed was awarded the CPhI Pharma Award for Best Company Category for its NEXUS needle-free infusion system for patients with and without diabetes.

References

https://in.investing.com/equities/steadymed-ltd

https://www.crunchbase.com/organization/steadymed-therapeutics

www.steadymed.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Ian Solomon (Founder)

Yossi Aldar (Founder)

Products/ Services

Biotechnology, Health Care, Pharmaceutical, Therapeutics

Number of Employees

0 - 50

Headquarters

Tel Aviv, Tel Aviv, Israel

Established

2005

Company Registration

SEC CIK number: 0001619087

Traded as

NASDAQ:STDY

Social Media

URL

www.steadymed.com

Last updated: Tue Feb 25 2025

We value your privacy

SteadyMed Therapeutics

Table of content

Summary